Susan Washer | CEO |
Bill Sullivan | CFO |
Mark Shearman | Chief Scientific Officer |
Matthew Luchini | BMO Capital Markets |
Yanan Zhu | Wells Fargo Securities |
David Nierengarten | Wedbush Securities |
Good afternoon, and welcome to the AGTC Fourth Quarter and Fiscal Year 2018 Financial Results Conference Call. Today’s call is being recorded.
Before we get started, I would like to remind everyone that during this conference call, AGTC may make forward-looking statements, including statements about the Company’s financial results, its future business strategies and operations, and its product development and regulatory progress. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors of AGTC’s annual report on Form 10-K for the fiscal year-ended June 30, 2018.
For introductions and opening remarks, I’d like to turn the call over to Susan Washer, Chief Executive Officer of AGTC.